Assessment of Chemotherapeutic and Hormonal Options Based on Individualized Risk Assessment

CME
Cancer treatment is moving in to the individualized or 'personalized' era. This activity discusses the use of an individualized, targeted approach to patients with breast cancer, with a focus on individual patient risk factors.
Duration
December 23, 2009 to December 23, 2010
Credits
Maximum of 1.0 AMA PRA Category 1 Credits™
Faculty
Ruth O'Regan, MD

This course is not part of OncologySTAT.
By clicking the button below you will be leaving this website.


Community CommentsTotal comments to date:

Program accredited by:

Joint sponsorship of Beth Israel Medical Center, St. Luke's and Roosevelt Hospitals, Massachusetts General Hospital Academy and Reed Medical Education.

Program supported by:

Our evidence-based curriculum is supported by an educational grant from Genentec and Pfizer

Cancer Type

  • Bladder
  • Bone
  • Breast
  • Breast (ER-Positive)
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • Hodgkin's Lymphoma
  • Kidney (Renal Cell)
  • Leukemia
  • Liver and Bile Duct
  • Lung
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myeloproliferative Diseases
  • Non-Hodgkin's Lymphoma
  • Pancreas
  • Pediatric Cancers
  • Prostate
  • Rare Cancers
  • Skin
  • Soft-Tissue Sarcoma
  • Stomach
  • Testicle
    • Forgot your password?
    Not a member? Free registration